Decline of Vaccine-Induced Antipneumococcal Antibody in Children With Nephrotic Syndrome
1986; Elsevier BV; Volume: 7; Issue: 6 Linguagem: Inglês
10.1016/s0272-6386(86)80186-x
ISSN1523-6838
AutoresJohn S. Spika, Neal A. Halsey, Chap T. Le, Alfred J. Fish, Gary M. Lum, Brian A. Lauer, Gerald Schiffman, G. Scott Giebink,
Tópico(s)Celiac Disease Research and Management
ResumoTwenty-five children with steroid-responsive idiopathic nephrotic syndrome were studied for persistence of antipneumococcal capsular polysaccharide antibody during relapse of their disease and at 1, 6, and 12 months after vaccination with the 14-valent pneumococcal vaccine. Nonrelapsers (group I) were compared to those who had at least one relapse but whose sera were obtained during remission (group II). Group II had a more rapid decline in total anticapsular antibody per month than group I (5.3% v 2.4%). Analysis by individual anticapsular types showed that differences between groups approached significance only for type 4 ( P = .07). Rates of decline of antibody against pneumococcal capsular polysaccharide varied among types. One year after vaccination, 50% of patients had < 300 ngAbN/mL against types 4, 6A, 7F 8, and 19F Sera obtained from seven patients during relapse had geometric mean antibody concentrations < 300 ngAbN/mL against those same types; two of these types have been reported to cause disease in vaccinated patients with nephrosis. Decline of antibody against pneumococcal capsular polysaccharide following vaccination varies by capsular type. Type-specific analysis should be used when monitoring serum antibody levels in these patients after vaccination.
Referência(s)